|March 4, 2013|
|10:57 EDT||MITK, SSYS, CBST, CWH, GSK||High option volume stocks: GSK CBST MITK CWH SSYS|
News For GSK;CBST;MITK;CWH;SSYS From The Last 14 Days
|October 13, 2015|
|05:55 EDT||SSYS||Piper Jaffray's 3D printing survey 'once again discouraging' |
Piper Jaffray analyst Troy Jensen says his firm's survey of 73 3D printing resellers was "once again discouraging" with the number of below plan responses out numbering above plan responses in Q3. On the positive side, the analyst saw a sequential improvement from the Q2 survey results for Stratasys (SSYS) system demand. On the negative side, the analyst says 3D Systems (DDD) system demand appears to have "remained challenged" in Q3. Channel checks point to demand for Stratasys' products beginning to reaccelerate, Jensen tells investors in a post-survey research note. However, his channel works points to continued "unhappy channel partners and system quality issues" for 3D Systems. The company has a long way to go until these issues will be fully resolved, he cautions. Jensen has Overweight ratings on Stratasys, voxeljet (VJET) and Materialise (MTLS), and a Neutral rating on 3D Systems.
|October 12, 2015|
|11:40 EDT||GSK||GlaxoSmithKline upgraded to Neutral from Underweight at JPMorgan|
|October 9, 2015|
|08:28 EDT||SSYS||Stratasys subsidiary MakerBot reducing staff by 20% globally|
Subscribe for More Information
|October 8, 2015|
|07:08 EDT||GSK||Codexis earns $6.5M milestone payment from GlaxoSmithKline |
Codexis (CDXS) announced that it successfully completed Wave 2 of the transfer of its proprietary CodeEvolver protein engineering platform technology to GlaxoSmithKline (GSK) in Q3 of 2015. Codexis expects to receive a $6.5M payment from GSK for completion of this milestone in Q4. Codexis has received a $6M upfront payment and a $5M Wave 1 technology transfer milestone payment from GSK since announcing the technology collaboration and license agreement with GSK in July 2014. The agreement grants GSK a license to use Codexis' CodeEvolver platform technology to develop novel enzymes for use in the manufacture of GSK's pharmaceutical and health care products. The CodeEvolver platform technology has been installed and is operational at a GSK facility in Pennsylvania. Codexis is eligible to receive an additional $7.5M payment from GSK subject to the satisfactory completion of the final CodeEvolver technology transfer milestone. Codexis also has the potential to receive numerous additional contingent milestone payments under the agreement with GSK that range from $5.75M-$38.5M per project based on GSK's successful application of the licensed technology. In addition, Codexis will be eligible to receive royalties based on net sales, if any, of a limited set of products developed by GSK using Codexis' CodeEvolver protein engineering platform technology.
|October 6, 2015|
|13:32 EDT||GSK||Biotechs plummet with TPP seen as industry negative |
Biotechs are falling intraday after reports that the Trans-Pacific Partnership, or TPP, has language that the exclusivity period for bioligics, or drugs derived from a biological sources, would be eight years, less than the twelve years it is currently in the United States. WHAT'S NOTABLE: In the U.S., biologics are protected from competition by follow-on products for twelve years from the time they are first granted marketing approval by the U.S. Food and Drug Administration, a protection that is distinct from patent protection. Recent reports on the TPP suggest that the protection will last five years with an additional safety monitoring period of up to three years before a biosimilar can be registered, which would effectively be an eight year exclusivity period. ANALYST REACTION: Piper Jaffray analyst Joshua Schimmer, however, said the development is a "step forward," especially since it does not overrule the 12 years' exclusivity for the drugs in the U.S. While the sector asked for twelve years' exclusivity to match the U.S., eight years is a "reasonable compromise," the analyst argued. His top picks were Alexion (ALXN), Celgene (CELG), and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC), and Ignyta (RXDX) in the small-cap sector. Further, Schimmer stated that more names look "increasingly compelling" amid the selloff. NOTABLE DECLINERS: Alexion is lower by 2.53%, Celgene is down 4.32%, Amgen is declining 1.91%, Biogen (BIIB) is down 3.4%, and Gilead Sciences (GILD) is falling 2.22%. STOCKS TO WATCH: Other publicly traded companies in the pharmaceutical space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
|12:29 EDT||SSYS||Primecap reports 5.l5% passive stake in Stratasys |
Subscribe for More Information
|09:01 EDT||SSYS||Stratasys, Adobe partner to bring 3D printing to creative professionals|
Stratasys Ltd. (SSYS) announced that they are partnering with Adobe (ADBE) to bring high quality, color 3D printing to creatives around the world. The announcement was made today in Los Angeles at Adobe MAX. The two companies are joining forces to eliminate the workflow and product barriers that prevent creative professionals from easily transforming their designs into vibrant and durable color 3D printed models. As the first step of this vision, starting immediately, Adobe Photoshop CC users will be able to send 3D files for production through Stratasys Direct Express.
|07:08 EDT||MITK||Mitek Systems receives mobile deposit reorders totaling $1.7M|
Mitek announced that it has received reorders from two Mobile Deposit partners, one in the U.S. and one in Canada, totaling $1.7M. These agreements closed in Mitek's Q4 and consisted of $1.4M in software license revenue and $0.3M in annual maintenance revenue.
|October 1, 2015|
|08:04 EDT||GSK||Pfizer completes acquisition of Nimerix, Mencevax from GSK|
Pfizer (PFE) announced that it has completed the acquisition of GlaxoSmithKline's (GSK) quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.
|September 30, 2015|
|12:41 EDT||GSK||GlaxoSmithKline exercises option for Liquidia Technologies' inhaled therapeutics|
Liquidia Technologies announced that GlaxoSmithKline has exercised its option under a Collaboration and Option Agreement signed in 2012 to exclusively license the right to research, develop, and commercialize inhaled therapeutics derived from the company's proprietary PRINT technology. Through this collaboration, Liquidia and GSK will continue to work together with the goal of advancing inhaled therapeutics into clinical studies. According to the agreement signed in June 2012, Liquidia was granted an upfront payment comprised of cash and equity, R&D funding, and potential development milestones and royalties. As a result of the GSK decision to exercise the option, Liquidia will receive an option fee, continued R&D funding, and potential product-based development and regulatory milestone payments. Liquidia has also retained the ability to independently develop an inhaled treatment for a particular disease field.
|09:47 EDT||SSYS||Stratasys management to meet with Oppenheimer|
Group luncheon to be held in New York on October 6 hosted by Oppenheimer.